THIS WEBSITE IS FOR BUSINESS & INDUSTRY PARTNERS. FOR CONSUMER PRODUCTS VISIT : BLIS Probiotics >
THIS WEBSITE IS FOR BUSINESS & INDUSTRY PARTNERS. FOR CONSUMER PRODUCTS VISIT : BLIS Probiotics >
If you’re evaluating ingredients for a gum-health formulation, you’ve probably noticed something awkward about the oral probiotic category: two products can both claim “probiotic support for healthy gums,” sit on the shelf at the same price, and produce very different outcomes in the studies behind them. One shows significant reductions in gingival bleeding at 12 weeks. Another shows nothing distinguishable from placebo.
That variability isn’t random, and it isn’t a knock on the category. It’s a signal that “oral probiotic” is doing far too much work as a term — covering strains, doses, delivery formats, and study populations that have almost nothing in common. For a formulator or brand manager, knowing where the variance actually comes from is the difference between a defensible claim and a marketing risk.
The first source of inconsistency starts upstream of any specific ingredient. The oral microbiome is its own ecosystem — roughly 700 bacterial species, organised into biofilm communities on teeth, gums, tongue, and soft tissue, and shaped by saliva flow, pH, oxygen gradients, and mechanical disruption from chewing and brushing.
That ecosystem doesn’t behave like the gut. Lactobacillus and Bifidobacterium strains optimised for gut transit and colonic survival aren’t selected to do anything in the mouth. Most don’t persist there, don’t compete with the bacteria that drive plaque or periodontal inflammation, and have no native role in the oral cavity. A probiotic chosen for gastrointestinal benefit is, in most cases, an oral pass-through.
This is why the most clinically active oral probiotics are sourced from the mouth itself. Native oral commensals — bacteria isolated from healthy human oral microbiomes — have the biological tools to occupy the niche they evolved in: adhesion to oral surfaces, antimicrobial peptide production targeted at oral pathogens, and metabolic activity matched to the saliva environment. This is the single biggest reason results across the category vary so much. Many products use strains that weren’t designed for the site they’re supposed to act on.
Even within oral-origin probiotics, “oral probiotic” is not a meaningful claim. Two strains of the same species can have completely different functional profiles. The relevant question for any gum-health formulation is: what does this specific strain do to the bacteria most directly involved in gingivitis and periodontal inflammation?
The work has been done on two strains in particular.
Streptococcus salivarius M18 (BLIS M18™) is a commensal isolated from the human oral cavity and selected for its activity against bacteria implicated in dental disease, including Streptococcus mutans. It produces antimicrobial peptides, contributes to oral pH regulation, and is associated with reduced plaque accumulation and improved gum-health markers in published trials.
Streptococcus salivarius K12 (BLIS K12™) is a different strain of the same species, isolated from the oral cavity of a healthy child. Its primary clinical record is in upper respiratory, ENT, and oral cavity applications — including throat and breath — through production of the lantibiotics salivaricin A2 and salivaricin B.
For gum-health positioning, BLIS M18™ is the strain with the evidence base. BLIS K12™ is complementary for formulators building broader oral and immune positioning, but it isn’t a substitute for periodontal-marker support and shouldn’t be marketed as one. Conflating the two — or treating them as interchangeable members of a generic “oral probiotic” category — is one of the more common sources of consumer disappointment with the category.
This is where category-level claims and product-level claims diverge most sharply. A formulation should be assessed against the studies on its specific strain, at its specific dose, in a population relevant to the indication. For BLIS M18™ and gum-health endpoints, the directly relevant trials are:
When you read these trials in aggregate, the pattern that emerges is consistent: BLIS M18™ supports a reduction in the markers clinicians use to measure gum-health status — bleeding, plaque, pocket depth — across age groups, study lengths, and dose ranges from 0.5B to 5B CFU/day. That is a different evidential profile from “clinically proven probiotic” copy on a product whose strain was studied for something else entirely.
The practical implication for formulation: when assessing an ingredient for gum-health positioning, ask for the strain-specific RCTs, with population, dose, duration, and endpoints. “Clinically studied” referring to a different strain — or a different application of the same strain — isn’t supporting evidence for the indication you’re claiming.
Once strain is settled, two factors account for most of the rest of the between-product variance: dose and delivery format.
Dose. Studies on BLIS M18™ for gum-health endpoints have used 0.5B to 5B CFU/day, with the Chen 2025 periodontitis study at the higher end (2.5B CFU twice daily) in a clinically advanced population. A finished product delivering substantially below the clinically supported dose, or below the level needed to maintain viable counts to end of shelf life, is unlikely to reproduce the effects seen in trial.
Delivery. Oral probiotics are site-of-action ingredients. The strain needs to be released in the mouth, contact the relevant surfaces, and remain viable long enough to compete with resident pathogens. The published trials on BLIS M18™ have predominantly used lozenges — a format that supports sustained oral contact. Capsules designed for gastric release deliver the strain to the wrong site. Powders, sachets, chewables, and lozenges each have different oral-residency profiles and different stability considerations, and these matter for whether the strain actually does what the trial demonstrated.
For brand teams: matching the dose and format used in the supporting studies isn’t a regulatory nicety, it’s the mechanism by which clinical evidence transfers to a finished product. Diverging from either weakens the chain from study to claim.
A simple diagnostic for evaluating products or ingredients in this category — whether you’re sourcing, formulating, or positioning:
A product that clears all six is a credible candidate for the claim. A product that clears two or three is operating on category halo rather than evidence — which is most of what’s driving the variance in consumer outcomes that this category has become known for.
For formulators building gum-health positioning, the case for native-strain, clinically supported oral probiotics isn’t that probiotics in general work — it’s that this strain, at this dose, in this format has the evidence. That’s the foundation of a claim that survives scrutiny from regulators, retailers, and the consumers buying a second bottle.
Babina, K., Salikhova, D., Makeeva, I., Zaytsev, A., Sokhova, I., Musaeva, S., Polyakova, M., & Novozhilova, N. (2024). A three-month probiotic (the Streptococcus salivarius M18 strain) supplementation decreases gingival bleeding and plaque accumulation: A randomized clinical trial. Dentistry Journal, 12(7), 207. https://pubmed.ncbi.nlm.nih.gov/39057009/
Chen, W., Sharma, L., Shao, P., Griffith, T., Love, R., Jain, R., Hale, J., & Sharma, A. (2025). Adjunctive use of Streptococcus salivarius M18 probiotic in the treatment of periodontitis: a randomized controlled trial. 3 Biotech. https://pubmed.ncbi.nlm.nih.gov/40443548/
Scariya, L., Nagarathna, D. V., & Varghese, M. (2015). Probiotics in periodontal therapy. International Journal of Pharma and Bio Sciences, 6(1), P242–P250.
Babina, K., Salikhova, D., Doroshina, V., Makeeva, I., Zaytsev, A., Uvarichev, M., Polyakova, M., & Novozhilova, N. (2023). Antigingivitis and antiplaque effects of oral probiotic containing the Streptococcus salivarius M18 strain: A randomized clinical trial. Nutrients, 15(18), 3882. https://doi.org/10.3390/nu15183882
Kiselnikova, L. P., & Toma, E. I. (2022). Changes in the main dental parameters of preschoolers with caries affected by long-term probiotic intake. Pediatric Dentistry and Dental Prophylaxis, 22(2), 97–102. https://doi.org/10.33925/1683-3031-2022-22-2-97-102
Burton, J. P., Wescombe, P. A., Moore, C. J., Chilcott, C. N., & Tagg, J. R. (2006). Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Applied and Environmental Microbiology, 72(4), 3050–3053. https://doi.org/10.1128/AEM.72.4.3050-3053.2006
BLIS K12™ and BLIS M18™ are trademarks of BLIS Technologies Limited. Because local laws and regulations related to the distribution, marketing and sale of ingredients and finished products vary, BLIS Technologies Limited disclaims any regulatory compliance, warranties, product guidance or instruction of any kind. This article is provided for business-to-business communication and educational purposes only without warranties of any kind. Users should seek legal and/or regulatory advice prior to the market introduction of any BLIS strain and before use of any claims to ensure compliance and thereafter on an ongoing basis when required.
